ADAMTS5 and cancer: Specific to CA disease, activated MEKK3-KLF4 signaling could impair PI3K-mTOR signaling, while also increasing expression of a second MEKK3 effector, the secreted versicanase ADAMTS5, increasing CA lesion formation58.